Month: February 2026

Draganfly Welcomes Lieutenant-General (Ret’d) Michel Gauthier to Military Advisory Board in Support of Canada’s Defence Industrial Strategy

Written by Customer Service on February 20, 2026. Posted in Public Companies.

Ottawa, ON, Feb. 20, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions, software, and robotics, today announced the appointment of Lieutenant-General (Ret’d) Michel Gauthier to its Military Advisory Board. The appointment comes as Canada advances its renewed Defence Industrial Strategy, a national framework focused on strengthening sovereign defence production, accelerating innovation, modernizing procurement, and reducing reliance on foreign supply chains. Lieutenant-General Gauthier brings more than 36 years of distinguished service with the Canadian Armed Forces. He served as Commander of the Canadian Expeditionary Force Command (CEFCOM), where he was responsible for operational command of Canadian Forces deployed internationally,...

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

Written by Customer Service on February 20, 2026. Posted in Public Companies.

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” please visit: https://ibn.fm/7N5vp Biotechnology mergers and acquisitions (“M&As”) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery...

Rio2 to Present at BMO’s Global Metals, Mining and Critical Minerals Conference and PDAC

Written by Customer Service on February 20, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce that its executive team lead by Alex Black, Executive Chairman of the Board, and Andrew Cox, President & CEO, will attend BMO’s 35th Global Metals, Mining, and Critical Minerals Conference next week in Hollywood, Florida, to discuss its future growth plans for the Fenix Gold Mine and the newly acquired Condestable Mine. Rio2 is set to present on Wednesday, February 25, 2026, at 9:00 AM in Ballroom C. Please note that the BMO Conference is by invitation only. The presentation will be webcast (Live & On-Demand) through the following link https://app.webinar.net/JWR323Xo9g1 Additionally, Rio2 will be participating in this year’s PDAC. Andrew Cox is scheduled to present...

CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

Written by Customer Service on February 20, 2026. Posted in Public Companies.

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited (“Sarborg”), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT’s clinical assets through Sarborg’s proprietary signature analysis and artificial intelligence capabilities. Sarborg’s business is built on the principle that biological, chemical and industrial signatures can function as a universal data language to identify, interpret and generate high-value opportunities. By analyzing, matching and learning from...

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

Written by Customer Service on February 20, 2026. Posted in Public Companies.

Regulatory clearance enables start of clinical testing and marks transition to clinical-stage company On track for initial clinical data to emerge from mid-2026Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company’s Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. Highlights:MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK Marks Zelluna’s transition from preclinical to clinical-stage...

NANO Nuclear Expands its Nuclear Policy Leadership Expertise with the Appointment of U.S. Government Veteran Sarah Lennon as its International Nuclear Policy Advisor

Written by Customer Service on February 20, 2026. Posted in Public Companies.

Figure 1NANO Nuclear Appoints Experienced DOE and NNSA Professional Sarah Lennon as its International Nuclear Policy Advisor.New York, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor (MMR) and technology company focused on developing clean energy solutions, today announced the appointment of Sarah Lennon as its International Nuclear Policy Advisor. Sarah is a seasoned national security and nuclear energy policy leader with three decades of distinguished service across the U.S. Government, bringing deep expertise in nuclear security, nonproliferation, international cooperation, and strategic planning. “It is a pleasure to join the NANO Nuclear team,” said Sarah Lennon, International Nuclear Policy Advisor of...

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Written by Customer Service on February 20, 2026. Posted in Public Companies.

Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a protocol amendment to its Phase 3 VERSATILE-003 clinical trial. The amendment includes PFS as an interim primary endpoint to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer. Median overall survival (mOS) remains the trial’s primary endpoint for full approval, consistent with the Company’s prior regulatory dialogue and post-meeting communication following its Type C meeting with the...

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Written by Customer Service on February 20, 2026. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform,...

National Healthcare Properties Reports Fourth Quarter and Full Year 2025 Results

Written by Customer Service on February 20, 2026. Posted in Earnings Releases And Operating Results.

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (the “Company”), a self-managed diversified healthcare real estate investment trust focusing on senior housing and outpatient medical facilities, today announced results for the fourth quarter and full year ended December 31, 2025. Michael Anderson, Chief Executive Officer and President, commented, “We are very pleased with the exceptional internal growth of our senior housing portfolio and the steady performance of our outpatient medical portfolio in 2025. We believe the fundamentals within the healthcare real estate industry, especially the senior housing sector, remain robust. We are excited about the year ahead and are committed to delivering strong performance across our business.” Financial Performance and Other Highlights Fourth...

Digital Currency X Technology Inc. Regains Compliance with Nasdaq Bid Price Requirement and Hearing Cancelled

Written by Customer Service on February 20, 2026. Posted in Public Companies.

New York, Feb. 20, 2026 (GLOBE NEWSWIRE) — Digital Currency X Technology Inc. (Nasdaq: DCX) (the “Company”), a pioneering digital asset treasury management company, today announced that it received a written notification from The Nasdaq Stock Market LLC, dated February 17, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and is therefore in full compliance with all applicable Nasdaq Capital Market listing requirements. As a result, the previously scheduled hearing before the Hearings Panel on February 24, 2026 has been canceled. The Company’s securities will continue to be listed and traded on the Nasdaq Capital Market without interruption. About Digital Currency X Technology Inc. Digital Currency X Technology Inc. (NASDAQ: DCX) is a pioneering...

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Month: February 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals